Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4620434 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNATSHRMAPK1ALDH1A1 | |
| SCHEMBL4620213 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNATSHRMAPK1ALDH1A1 | |
| SCHEMBL21094 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNATSHRMAPK1ALDH1A1 | |
| SCHEMBL4620431 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNATSHRMAPK1ALDH1A1 | |
| SCHEMBL4620207 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNATSHRMAPK1ALDH1A1 | |
| Diclocymet SCHEMBL674273 | 0.83 | MEN1 (0.50) | LMNAL3MBTL1MEN1KMT2A | |
| Diclocymet SCHEMBL4165786 | 0.83 | MEN1 (0.50) | LMNAL3MBTL1MEN1KMT2A | |
| Diclocymet SCHEMBL42437 | 0.83 | MEN1 (0.50) | LMNAL3MBTL1MEN1KMT2A | |
| Diclocymet SCHEMBL674274 | 0.83 | MEN1 (0.50) | LMNAL3MBTL1MEN1KMT2A | |
| Diclocymet SCHEMBL8921616 | 0.83 | MEN1 (0.50) | LMNAL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263608-A1 | 16-KETO ASPERGILLIMIDES AND HARMFUL ORGANISM CONTROL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2377398-A1 | 16-KETOASPERGILLIMIDE AND PEST EXTERMINATING AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | Meiji Seika Pharma Co., Ltd. (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20090082389-A1 | PESTICIDAL SUBSTITUTED PIPERIDINES | MERIAL LIMITED | 2009-03-26 | — | — | US | disclosed |
| EP-1848274-A1 | PESTICIDAL SUBSTITUTED PIPERIDINES | Merial Ltd. (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006087162-A1 | PESTICIDAL SUBSTITUTED PIPERIDINES | MERIAL LTD. (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082389-A1 | PESTICIDAL SUBSTITUTED PIPERIDINES | PIR, ACHE, PREP | SMN1; SMN2 2225/4885LMNA 2818/4885TSHR 1299/4885 |
| US-20110263608-A1 | 16-KETO ASPERGILLIMIDES AND HARMFUL ORGANISM CONTROL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | CYP51A1, AKR7A2, CYP2C18 | SMN1; SMN2 3197/4885LMNA 4183/4885TSHR 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.